Cargando…

Copious Podocyturia without Proteinuria and with Normal Renal Function in a Young Adult with Fabry Disease

The time for starting a patient with Fabry disease on enzyme replacement therapy is still a matter of debate, particularly when no overt classical clinical signs or symptoms are present. With respect to Fabry nephropathy, a dual problem coexists: the reluctance of many nephrologists to start enzyme...

Descripción completa

Detalles Bibliográficos
Autores principales: Trimarchi, H., Canzonieri, R., Muryan, A., Schiel, A., Araoz, A., Forrester, M., Karl, A., Lombi, F., Andrews, J., Pomeranz, V., Rengel, T., Zotta, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443757/
https://www.ncbi.nlm.nih.gov/pubmed/26064721
http://dx.doi.org/10.1155/2015/257628
Descripción
Sumario:The time for starting a patient with Fabry disease on enzyme replacement therapy is still a matter of debate, particularly when no overt classical clinical signs or symptoms are present. With respect to Fabry nephropathy, a dual problem coexists: the reluctance of many nephrologists to start enzyme replacement infusion until signs of renal disease appear as the appearance of proteinuria or an elevation in serum creatinine and the lack of validated biomarkers of early renal damage. In this regard, proteinuria is nowadays considered as an early and appropriate marker of kidney disease and of cardiovascular morbidity and mortality. However, in this report we demonstrate that podocyturia antedates the classical appearance of proteinuria and could be considered as an even earlier biomarker of kidney damage. Podocyturia may be a novel indication for the initiation of therapy in Fabry disease.